Shandong Sito Bio-technology Co., Ltd. Class A

Shandong Sito Bio-technology Co., Ltd. Class A

SSZSE:300583
10.65
CNY
-0.22
(-2.02%)
0.16EPS
87.90P/E
2.60BMarket Cap
Shandong Sito Bio-technology Co., Ltd. Class A
SZSE:300583
(Shenzhen Stock Exchange)

Recent

price

10.65

P/E

ratio

87.90

div

yld

1.23%

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.09
1.66
4.07
5.22
4.42
4.7
6.15
5.68
5.33
7.06
7.5
7.02
5.14
5.42
6.09
Revenue per Share
-0.01
0.24
1.29
1.46
0.79
0.55
0.74
0.32
-1.05
0.21
0.24
0.25
-0.47
-0.39
0.16
Basic EPS, GAAP
-0.32
-0.13
-0.43
-0.34
-0.36
-0.39
-4.17
-0.9
0.07
-0.95
0.01
-1.02
0.68
0.42
- -
Free Cash Flow per Basic Share
- -
0.03
0.05
0.09
0.11
0.09
0.15
0.28
0.22
0.14
0.25
0.18
0.6
0.15
0.13
Dividend per Share
0.25
0.77
2.27
3.74
3.4
9.78
11.04
10.63
9.56
9.81
10.05
10.61
9.69
9.29
9.3
Book Value per Share
0.16
0.68
1.89
3.22
3.02
9.36
10.47
9.37
8.57
8.76
9.04
9.55
8.7
8.33
8.36
Tangible Book Value per Share
128
171
128
128
128
167
171
170
171
170
175
182
189
188
187
Basic Weighted Avg Shares
11
284
521
668
568
786
1,052
966
913
1,203
1,312
1,280
971
1,017
1,138
Sales/Revenue/Turnover
-5.61
22.81
39.03
35.48
22.89
11.8
13.8
8.96
-8.71
8.07
6.38
6.62
-0.79
0.34
8.31
Operating Margin (%)
- -
3
17
34
44
60
68
83
143
135
163
174
175
168
- -
Depreciation Expense
-1
42
166
187
101
92
126
55
-180
36
42
46
-89
-73
29
Net Income, GAAP
- -
25.77
14.58
14.72
16.84
16.96
15.19
24.2
- -
34.08
11.37
9.22
- -
- -
38.5
Effective Tax Rate (%)
-13.53
14.66
31.81
27.99
17.81
11.71
11.98
5.73
-19.69
3.01
3.2
3.56
-9.15
-7.19
2.56
Profit Margin (%)
4
69
48
190
204
1,029
943
564
199
25
55
411
261
279
248
Working Capital
- -
45
100
140
158
- -
85
146
196
164
124
116
80
135
116
LT Debt
32
99
291
507
603
1,707
1,961
1,887
1,691
1,732
1,771
2,065
1,884
1,797
1,800
Total Equity
- -
38.52
54.56
32.57
12.3
6.37
5.78
1.98
- -
1.55
1.79
1.11
- -
- -
1.15
Return on Invested Capital (%)
- -
44.56
57.66
35.19
15.07
7.76
6.55
3.3
- -
2.38
3.04
2.88
- -
- -
1.76
Return on Capital (%)
- -
63.31
85.08
48.63
19.12
8.11
7.01
2.96
-10.35
2.18
2.47
2.44
-4.61
-4.06
1.64
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
650
587
628
LT Borrowings
126
137
116
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
190
190
190
Market Capitalization
2,682
2,130
2,599

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,251
1,268
1,292
Cash, Cash Equivalents & STI
237
261
234
Accounts Receivable, Net
343
309
272
Inventories
396
458
544
Total Current Liabilities
985
1,005
1,045
Payables & Accruals
- -
- -
- -
ST Debt
650
587
628
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.07%
1.57%
-4.64%
Free Cash Flow
-1,225.54%
-2,624.18%
-38.82%
Net Income, GAAP
-90.7%
-81.56%
-17.6%
Sales/Revenue/Turnover
6.25%
3.79%
4.77%
Total Cash Common Dividend
36.51%
38.63%
-75.4%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
244
322
198
206
971
2025
260
248
- -
268
1,017
2026
328
285
257
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.05
0.01
-0.55
-0.47
2025
-0.15
-0.13
- -
-0.02
-0.39
2026
0.02
0.14
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.03
0.48
0.03
0.6
2025
0.04
0.04
- -
0.03
0.15
2026
0.04
0.04
0.03
- -
- -
Business
Shandong Sito Bio-technology Co., Ltd. researches, develops, produces, and sells steroid biomedicine intermediates and raw materials for pharmaceutical companies using genetic engineering and microbial transformation technologies. The company offers core products including androstenedione (4-AD), 1,4-androstadiene-3,17-dione (ADD), 9-hydroxyandrostenedione (9OH-AD), 17α-hydroxyprogesterone, 17α-acetoxyprogesterone, progesterone intermediate (2DM), tetraene acetate (3TR), medroxyprogesterone (8DM), anecort acetate, tylvalosin tartrate, bisnoralcohol, norandrostenedione, estra-4,9-diene-3,17-dione, androsta-1,4-diene-3,17-dione, 16β and 16α methyl epoxide, and hexahydro-3α-methyl derivatives. Founded in 2002 and headquartered in Heze City, Shandong Province, China, the company operates primarily in the biopharmaceutical industry, serving global pharmaceutical manufacturers with production facilities covering 200,000 square meters and a dedicated R&D team. Shandong Sito maintains recognition as a national high-tech enterprise, Shandong Engineering Laboratory, and a leading enterprise in Shandong's top industrial clusters, with stable partnerships alongside gene sequencing firms and research institutes including Wuhan University and the Chinese Academy of Sciences. The company listed on the Shenzhen Stock Exchange in 2017 (ticker: 300583.SZ) and completed the acquisition of an 80% stake in Lisapharma S.p.A. in recent years to expand its operations.